Search clinical trials for: Placebo of CDP870

Total 183395 results

Otsuka Pharmaceutical Co., Ltd.
UCB Japan Co. Ltd.

Completed

Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Japan
Otsuka Pharmaceutical Co., Ltd.
UCB Japan Co. Ltd.

Completed

Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

Japan
UCB Pharma

Completed

Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease

Crohn Disease

United States, Australia, Italy, Ukraine, Germany, Belgium, Israel, Romania, Canada, New Zealand, Brazil, Estonia, Russian Federation, Chile, Austria, Poland, Hungary, Latvia, Czechia, Finland
UCB Pharma

Completed

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease (Welcome2)

Crohn's Disease

United States, France, Italy, United Kingdom, Belgium, Germany, Spain, Switzerland, Canada, Netherlands, Austria, Sweden
UCB Pharma SA

Completed

A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease (PRECiSE 4)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine
UCB Pharma SA

Completed

A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] (PRECiSE 3)

Crohn's Disease

United States, Australia, Austria, Belarus, Belgium, Bulgaria, Czechia, Denmark, Estonia, Germany, Hungary, Israel, Italy, New Zealand, Norway, Poland, Russian Federation, Serbia, Singapore, Slovenia, South Africa, Spain, Ukraine, Canada and more
UCB BIOSCIENCES GmbH

Completed

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS (C-AXSPAND)

Axial Spondyloarthritis | Nonradiographic Axial Spondyloarthritis | Nr-axSpA

United States, Australia, Bulgaria, Canada, Czechia, Hungary, Poland, Russian Federation, Taiwan
UCB Pharma SA
Parexel

Completed

A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects

Healthy Subjects

China
UCB Pharma

Completed

Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study (CERTAIN)

Rheumatoid Arthritis

France, Poland, Germany, Austria, Italy
UCB Biopharma S.P.R.L.

Completed

An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-1)

Psoriasis | Plaque Psoriasis

United States, Canada, Czechia, Germany, Hungary
UCB Biopharma S.P.R.L.

Completed

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-2)

Psoriasis | Plaque Psoriasis

United States, Austria, Canada, Poland
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Korea, Republic of
UCB Pharma

Terminated

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease (COSPAR1)

Crohn's Disease

United States, Germany, Canada
UCB Pharma

Completed

Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

Crohn's Disease

United States, France, Italy, United Kingdom, Belgium, Germany, Spain, Switzerland, Canada, Netherlands, Denmark, Austria, Norway, Sweden
UCB BIOSCIENCES GmbH
Parexel

Completed

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo (C-OPTIMISE)

Ankylosing Spondylitis | Axial Spondyloarthrithis

United States, Belgium, Bulgaria, Czechia, France, Germany, Hungary, Netherlands, Poland, Romania, Spain, Taiwan, Turkey, United Kingdom
UCB Pharma

Completed

Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study (CERTAIN 2)

Rheumatoid Arthritis

Poland, Germany, Austria, France, Italy
UCB Celltech

Terminated

The Use of Certolizumab Pegol for Treatment of Active Crohn's Disease in Children and Adolescents (NURTURE)

Crohn's Disease

United States, Canada, New Zealand, Australia
UCB Pharma

Completed

Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease

Crohn's Disease

Japan
UCB Biopharma S.P.R.L.

Completed

A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis

Moderate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic Psoriasis

Japan
UCB BIOSCIENCES GmbH
PPD

Completed

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

Crohn Disease

Russian Federation, Belgium, United States, Australia, Austria, Brazil, Canada, Czechia, Estonia, Germany, Hungary, Israel, Italy, Latvia, New Zealand, Poland, Romania, Ukraine
UCB Pharma

Completed

A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

Crohn's Disease
UCB Pharma

Completed

Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870).

Crohn's Disease
UCB Pharma

Completed

Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis

Rheumatoid Arthritis
UCB Biopharma SRL

Completed

A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice (CIMREAL)

Plaque Psoriasis

Belgium, Canada, Czechia, France, Germany, Greece, Italy, Spain, United Kingdom
UCB Biopharma SRL

Completed

A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU (C-VIEW)

Axial Spondyloarthritis (axSpA) | Anterior Uveitis (AU)

Czechia, Germany, Netherlands, Poland, Spain
UCB Pharma

Completed

Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)

Crohn's Disease

Japan
UCB Japan Co. Ltd.

Completed

Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease

Crohn's Disease

Japan
UCB Pharma

Completed

Bio-availability Comparison of Three Formulations of Certolizumab Pegol in Healthy Volunteers

Bioavailability Study on Healthy Volunteers

France
UCB Pharma

Completed

Mucosal Healing Study in Crohn's Disease (CD) (MUSIC)

Crohn's Disease

France, Germany, Belgium
UCB Pharma

Completed

Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA) (MARVELOUS)

Rheumatoid Arthritis

Denmark, Netherlands, Poland, Sweden
UCB Pharma

Completed

Comparison Bioequivalence Study: Pre-filled Syringe (Reference) Versus Auto-injection Device (Test)

Healthy

France
Astellas Pharma Inc
UCB Japan Co. Ltd.

Completed

Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870

Active Rheumatoid Arthritis

Japan
UCB Pharma

Completed

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease (COSPAR II)

Crohn's Disease

United States, Germany, Canada
Korea Otsuka Pharmaceutical Co., Ltd.

Completed

Open-label, Extension Study of CDP870 in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
UCB Pharma

Completed

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Canada, Belgium, Argentina, Israel, Bulgaria, Chile, Russian Federation, Australia, Czechia, Latvia, Ukraine, Croatia
UCB Pharma

Completed

Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis

Arthritis, Rheumatoid
UCB Biopharma SRL

Completed

A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

United States, Czechia, Germany, Greece, Moldova, Republic of, Netherlands, Poland, Russian Federation
Cell Genesys

Completed

Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer

Prostate Cancer
Astellas Pharma Inc
UCB Japan Co. Ltd.

Completed

Long-term Treatment Study of Certolizumab Pegol Without Coadministration of Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis

Japan
Cell Genesys

Terminated

Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

Prostate Cancer

United States
Boehringer Ingelheim

Completed

Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin ER in Healthy Subjects

Healthy
Cochlear

Completed

Clinical Assessment of the External Sound Processor Worn by Patients Implanted With Codacs

Severe to Profound Mixed Hearing Loss

Germany
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases

Acute Myeloid Leukemia | Multiple Myeloma | Non-hodgkin's Lymphoma

China
Astellas Pharma Inc
UCB Japan Co. Ltd.

Completed

Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis

Rheumatoid Arthritis

Japan
UCB Biopharma S.P.R.L.

Completed

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (CIMPACT)

Psoriasis | Plaque Psoriasis

United States, Bulgaria, Czechia, France, Germany, Hungary, Netherlands, Poland, United Kingdom
Nathan Wei, MD, FACP, FACR:
University of California, San Diego

Completed

Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

Rheumatoid Arthritis

United States
Boehringer Ingelheim

Completed

Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers

Healthy
Changhai Hospital
UTC Therapeutics Inc.

Recruiting

Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms

CD70-positive Advanced Urologic Neoplasms

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China
Shenzhen Geno-Immune Medical Institute

Recruiting

PSMA/CD70 Bi-specific CAR-T Cell Therapy

Cancer Disease

China

3

Subscribe